| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
WHITEHOUSE STATION, N.J.—Pushing itself further into the growing RNAi market, Merck announced it has entered into a definitive agreement to acquire Sirna Therapeutics. The deal will see the smaller biotech company become a fully owned subsidiary of the pharma giant in a $1.1-billion move.
 
"RNAi is a powerful enabler of drug discovery in cells, in animals, and in humans," said Dr. Stephen H. Friend, EVP and franchise head for oncology and neuroscience at Merck Research Laboratories. "We can potentially use this technology to target the activity of genes which control the activity of cancer cells, and so produce their destruction without damaging normal cells."
 
Merck has been aggressive in the RNAi marketplace, which according to a recent report by Frost & Sullivan, is expected to reach almost $300 million by 2012, having signed several development deals with Alnylam Pharmaceuticals. [Look to the December issue of Drug Discovery News for more about this deal.]

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue